

# Dae-Seog Heo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/105929/dae-seog-heo-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318  
papers

12,754  
citations

56  
h-index

100  
g-index

330  
ext. papers

14,311  
ext. citations

4.1  
avg, IF

5.94  
L-index

#	Paper	IF	Citations
318	Hospice-Palliative Medicine as a Model of Value-Based Healthcare.. <i>Journal of Korean Medical Science</i> , <b>2022</b> , 37, e111	4.7	1
317	Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. <i>The Korean Journal of Hospice and Palliative Care</i> , <b>2022</b> , 25, 1-11	0.5	2
316	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. <i>Scientific Reports</i> , <b>2021</b> , 11, 19712	4.9	7
315	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, 975-984	2.5	1
314	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , <b>2021</b> , 106, 2277-2280	6.6	1
313	Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , <b>2021</b> , 53, 584-592	5.2	1
312	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1605-1617	7.4	2
311	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. <i>Cancer Research and Treatment</i> , <b>2021</b> , 53, 983-990	5.2	1
310	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 2514	4.9	1
309	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1755-1769	7.4	2
308	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 699-711	4.4	2
307	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1859-1871	8.9	2
306	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 619-630	3.2	3
305	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, 175-181	2.5	4
304	Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. <i>Chinese Clinical Oncology</i> , <b>2020</b> , 9, 15	2.3	5
303	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , <b>2020</b> , 34, 2184-2197	10.7	24
302	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 1389	3.2	

301	Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients. <i>Cancer Research and Treatment</i> , <b>2020</b> , 52, 917-924	5.2	12
300	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. <i>Neuro-Oncology</i> , <b>2020</b> , 22, iii328-iii329	1	78
299	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 62-71	3.2	17
298	Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2020</b> , 50, 185-192	2.8	8
297	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , <b>2020</b> , 495, 135-144	9.9	3
296	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3482-3489	3.2	5
295	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , <b>2020</b> , 10, 10838-10848	12.1	18
294	Clinical Application of Next-Generation Sequencing-Based Panel to Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 937-944	6.1	7
293	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2117-2123	3.2	4
292	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 136, 122-128	5.9	19
291	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 7680	4.9	26
290	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 331-338.e4	4.9	32
289	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. <i>Cytotherapy</i> , <b>2019</b> , 21, 603-611	4.8	9
288	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , <b>2019</b> , 24, 751-e231	5.7	10
287	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e442-e451	4.9	10
286	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1556-1566	8.9	15
285	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , <b>2019</b> , 34, 885-893	2.5	3
284	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , <b>2019</b> , 34, 1313-1323	2.5	10

283	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , <b>2019</b> , 34, 1116-1124	2.5	3
282	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 169-177	5.2	3
281	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 119-127	5.2	18
280	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 951-962	5.2	27
279	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1231-1240	5.2	9
278	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. <i>Korean Journal of Internal Medicine</i> , <b>2019</b> , 34, 894-901	2.5	
277	Do Korean Medical Schools Provide Adequate End-of-Life Care Education? A Nationwide Survey of the Republic of Korea's End-of-Life Care Curricula. <i>The Korean Journal of Hospice and Palliative Care</i> , <b>2019</b> , 22, 207-218	0.5	0
276	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , <b>2019</b> , 24, e740-e748	5.7	21
275	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , <b>2019</b> , 4, e000575	6	5
274	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , <b>2019</b> , 19, 19	4.8	40
273	Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. <i>Oral Oncology</i> , <b>2019</b> , 89, 84-94	4.4	11
272	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , <b>2019</b> , 24, 20-e29	5.7	21
271	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 736-744	3.2	22
270	CD21-independent Epstein-Barr virus entry into NK cells. <i>Cellular Immunology</i> , <b>2018</b> , 327, 21-25	4.4	8
269	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , <b>2018</b> , 59, 202-210 <sup>3</sup>		5
268	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , <b>2018</b> , 3, e000332	6	32
267	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , <b>2018</b> , 132, 1617-1617	2.2	4
266	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8575-8575	2.2	6

265	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , <b>2018</b> , 13, e0189766	3.7	28
264	Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 614-623	5.2	18
263	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 720-728	5.2	9
262	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 459-470	7.4	82
261	Consensus guidelines for the definition of the end stage of disease and last days of life and criteria for medical judgment. <i>Journal of the Korean Medical Association</i> , <b>2018</b> , 61, 509	0.5	10
260	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 670-680	5.2	4
259	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 53-63	1.9	24
258	Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2624-2632	1.9	5
257	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 980-986	5.8	37
256	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , <b>2017</b> , 8, 1050	17.4	75
255	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 1033-1043	5.2	10
254	The fantasy of a new healthcare policy in Korea. <i>Journal of the Korean Medical Association</i> , <b>2017</b> , 60, 936-940	0.5	1
253	How to build successful hospice-palliative care systems in Korea. <i>Journal of the Korean Medical Association</i> , <b>2017</b> , 60, 352	0.5	1
252	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3065-3074	2.2	229
251	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 520-528	8.9	15
250	The Necessity for End-of-Life Care Education: A Preliminary Analysis with Interns at Two University Hospitals. <i>The Korean Journal of Hospice and Palliative Care</i> , <b>2017</b> , 20, 111-121	0.5	2
249	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 97920-97927	3.3	49
248	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , <b>2017</b> , 32, 514-522	2.5	12

247	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 129-140	5.2	3
246	The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 502-508	5.2	21
245	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 416-422	5.2	24
244	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , <b>2016</b> , 38, 277-84	4.2	10
243	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , <b>2016</b> , 16, 116	4.8	25
242	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 304-11	5.2	8
241	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 215-24	12.5	90
240	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 263-270.e2	4.9	82
239	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , <b>2016</b> , 93, 1-8	5.9	11
238	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2261-70	12.9	164
237	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , <b>2016</b> , 16, 170	4.8	24
236	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 873-83	4.9	13
235	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1956-60	1.9	7
234	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9013-9013	2.2	11
233	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 15901-14	3.3	101
232	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 8389-8397	5.6	19
231	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , <b>2016</b> , 31, 1140-1149	2.5	23
230	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 88-97	5.2	12

229	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6078-6078	2.2	
228	Korean Cancer Patients' Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10067-10067	2.2	
227	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. <i>Blood</i> , <b>2016</b> , 128, 4222-4222	2.2	
226	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 907-16	5.2	27
225	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , <b>2016</b> , 31, 570-8	2.5	26
224	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. <i>BMC Cancer</i> , <b>2016</b> , 16, 363	4.8	32
223	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , <b>2016</b> , 68, 1079-89	7.3	102
222	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , <b>2016</b> , 16, 425-33	3.8	13
221	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 245-252.e1	4.9	15
220	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 469, 581-590	5.1	53
219	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. <i>Journal of Clinical Neuroscience</i> , <b>2016</b> , 34, 145-150	2.2	1
218	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 161-6	3.2	16
217	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2379-87	12.9	89
216	Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1778-86	1.9	35
215	Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 91-8	4	16
214	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , <b>2015</b> , 20, 1119-20	5.7	17
213	Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. <i>Annals of Hematology</i> , <b>2015</b> , 94, 575-81	3	36
212	Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study. <i>Palliative and Supportive Care</i> , <b>2015</b> , 13, 1103-1115	2.5	8

211	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. <i>European Journal of Immunology</i> , <b>2015</b> , 45, 2335-42	6.1	27
210	Personalized cancer medicine: present status and future perspectives. <i>Journal of the Korean Medical Association</i> , <b>2015</b> , 58, 1021	0.5	1
209	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 555-63	5.2	40
208	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133371	3.7	7
207	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , <b>2015</b> , 194, 1112-9	2.5	17
206	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. <i>Lung Cancer</i> , <b>2015</b> , 90, 381-7	5.9	39
205	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2032-8	1.9	33
204	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 15035-49	3.3	77
203	Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy. <i>Radiation Oncology Journal</i> , <b>2015</b> , 33, 98-108	2.5	18
202	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , <b>2015</b> , 30, 891-8	2.5	8
201	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 182-8	5.2	3
200	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 670-5	5.2	23
199	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 630-7	5.2	17
198	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 607-15	5.2	76
197	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , <b>2015</b> , 35, 175-82	2.3	26
196	Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1567-74	4.9	11
195	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. <i>Lung Cancer</i> , <b>2014</b> , 85, 320-5	5.9	5
194	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. <i>Journal of Korean Medical Science</i> , <b>2014</b> , 29, 1094-101	4.7	14



193	Terminal cancer patients' and their primary caregivers' attitudes toward hospice/palliative care and their effects on actual utilization: A prospective cohort study. <i>Palliative Medicine</i> , <b>2014</b> , 28, 976-985	5.5	13
192	Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 940-3	1.9	6
191	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. <i>Lung Cancer</i> , <b>2014</b> , 86, 363-8	5.9	15
190	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1430-7	27.4	107
189	A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. <i>Oncologist</i> , <b>2014</b> , 19, 1129-30	5.7	13
188	The Understanding of Terminal Cancer and Its Relationship with Attitudes toward End-of-Life Care Issues. <i>Medical Decision Making</i> , <b>2014</b> , 34, 720-30	2.5	9
187	Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, e1-6	4.9	1
186	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7500-7500	2.2	3
185	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , <b>2014</b> , 46, 323-30	5.2	17
184	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9543-9543	2.2	
183	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17032-e17032	2.2	
182	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1437-44	3.9	43
181	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , <b>2013</b> , 119, 1195-202	6.4	117
180	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 183-90	3.9	30
179	Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1069-74	8.9	88
178	A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6069-6069	2.2	2
177	International comparison on the factors influencing reimbursement of expensive cancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6614-6614	2.2	1
176	Clinical Implications of VEGF, TGF- $\beta$ , and IL-1 $\beta$ in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2013</b> , 45, 325-33	5.2	34

175	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives <b>2013</b> , 21, 1437		1
174	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8521-8521	2.2	
173	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2098-2098	2.2	
172	The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1590-1590	2.2	
171	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e18555-e18555	2.2	
170	Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. <i>Cancer Science</i> , <b>2012</b> , 103, 155-60	6.9	15
169	The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. <i>Cellular Oncology (Dordrecht)</i> , <b>2012</b> , 35, 1-8	7.2	25
168	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , <b>2012</b> , 33, 121-9	2.9	65
167	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 303-13	4.8	52
166	Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 29-37	3.9	16
165	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 395-403	3.9	16
164	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , <b>2012</b> , 77, 288-92	5.9	102
163	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 528-38	21.7	777
162	Integration of palliative and supportive cancer care in Asia. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 445-6	21.7	26
161	Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. <i>International Journal of Oncology</i> , <b>2012</b> , 41, 76-82	4.4	25
160	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <i>Lung Cancer</i> , <b>2012</b> , 77, 433-7	5.9	19
159	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , <b>2012</b> , 77, 460-3	5.9	71
158	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. <i>Lung Cancer</i> , <b>2012</b> , 77, 572-7	5.9	58

157	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , <b>2012</b> , 118, 3579-86	6.4	41
156	Effect of advanced cancer patients' awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 1309-16	3.9	23
155	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3337-44	2.2	214
154	Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e147-50	2.2	43
153	Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2012</b> , 42, 948-54	2.8	10
152	Complementary and alternative medicine use among cancer patients at the end of life: Korean national study. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2012</b> , 13, 1419-24	1.7	17
151	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7566-7566	2.2	
150	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5552-5552	2.2	
149	PPAR $\alpha$ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 406, 389-95	3.4	29
148	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R22	8.3	158
147	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. <i>Lung Cancer</i> , <b>2011</b> , 71, 65-9	5.9	27
146	Characteristics and issues of guideline to withdrawal of a life-sustaining therapy. <i>Journal of the Korean Medical Association</i> , <b>2011</b> , 54, 747	0.5	23
145	Depression, suicide, and Korean society. <i>Journal of the Korean Medical Association</i> , <b>2011</b> , 54, 358	0.5	11
144	A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF- $\beta$ . <i>Tumori</i> , <b>2011</b> , 97, 350-357	1.7	14
143	The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines. <i>Anti-Cancer Drugs</i> , <b>2011</b> , 22, 416-23	2.4	6
142	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1474-80	8.9	131
141	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 905-12	8.9	53
140	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Science</i> , <b>2011</b> , 102, 1972-6	6.9	8

139	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 103, 595-602	4.8	25
138	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2011</b> , 137, 1301-8	4.9	24
137	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , <b>2011</b> , 11, 435	4.8	17
136	Clinical dissection of multicentric Castleman disease. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1517-22	1.9	27
135	VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. <i>Diagnostic Molecular Pathology</i> , <b>2011</b> , 20, 143-7		3
134	Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2474-80	2.2	60
133	The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2011</b> , 336, 516-23	4.7	25
132	EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 548-54 <sup>2.8</sup>		7
131	Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2965-71	2.2	230
130	Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients. <i>Cmaj</i> , <b>2011</b> , 183, E673-9	3.5	50
129	Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. <i>Hematology</i> , <b>2011</b> , 16, 73-9	2.2	5
128	Use of a decision aid to help caregivers discuss terminal disease status with a family member with cancer: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4811-9	2.2	32
127	MicroRNA-146a downregulates NFB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4761-71	12.9	153
126	Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 245-52	2.8	5
125	Depression and suicide in Korean society. <i>Journal of the Korean Medical Association</i> , <b>2011</b> , 54, 356	0.5	3
124	Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma. <i>Cancer Science</i> , <b>2010</b> , 101, 482-7	6.9	9
123	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. <i>Cancer Science</i> , <b>2010</b> , 101, 1199-203	6.9	36
122	Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1950-7	2.2	118

121	Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40, 542-8	2.8	19
120	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2010</b> , 68, 427-32	5.9	5
119	Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 320-5	8.9	41
118	Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line. <i>Oncology Reports</i> , <b>2010</b> , 23, 1139-43	3.5	14
117	The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives. <i>Supportive Care in Cancer</i> , <b>2010</b> , 18, 189-96	3.9	26
116	Impact of caregivers' unmet needs for supportive care on quality of terminal cancer care delivered and caregiver's workforce performance. <i>Supportive Care in Cancer</i> , <b>2010</b> , 18, 699-706	3.9	55
115	A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC. <i>Tumor Biology</i> , <b>2010</b> , 31, 659-66	2.9	4
114	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , <b>2010</b> , 10, 448	4.8	34
113	Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , <b>2010</b> , 32, 1534-43	4.2	20
112	Justifying the Information on Hospice Care that doctors should provide to Terminally Ill Patients. <i>Korean Journal of Medical Ethics</i> , <b>2010</b> , 13, 107-122	0	1
111	Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. <i>Chemotherapy</i> , <b>2009</b> , 55, 145-54	3.2	2
110	Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. <i>Journal of Immunology</i> , <b>2009</b> , 182, 6114-20	5.3	12
109	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. <i>BMC Cancer</i> , <b>2009</b> , 9, 450	4.8	16
108	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , <b>2009</b> , 9, 73	4.8	62
107	Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2009</b> , 31, 1121-8	4.2	27
106	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 116, 153-60	4.4	39
105	Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. <i>Annals of Hematology</i> , <b>2009</b> , 88, 829-38	3	14
104	Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. <i>Cancer Science</i> , <b>2009</b> , 100, 2242-8	6.9	54

103	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , <b>2009</b> , 29, 443-9	2	31
102	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , <b>2009</b> , 65, 80-4	5.9	105
101	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , <b>2009</b> , 65, 204-7	5.9	24
100	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2009</b> , 65, 242-6	5.9	11
99	Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. <i>International Journal of Molecular Medicine</i> , <b>2009</b> , 23, 805-10	4.4	12
98	Patient Autonomy and Advance Directives in Korea. <i>Journal of the Korean Medical Association</i> , <b>2009</b> , 52, 865	0.5	46
97	Evidence-based Healthcare in Korea. <i>Journal of the Korean Medical Association</i> , <b>2009</b> , 52, 934	0.5	
96	Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. <i>Laryngoscope</i> , <b>2008</b> , 118, 663-70	3.6	42
95	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , <b>2008</b> , 8, 148	4.8	56
94	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , <b>2008</b> , 8, 374	4.8	41
93	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , <b>2008</b> , 60, 401-7	5.9	72
92	Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. <i>Lung Cancer</i> , <b>2008</b> , 61, 30-4	5.9	76
91	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. <i>Lung Cancer</i> , <b>2008</b> , 62, 381-4	5.9	17
90	Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. <i>Cancer Investigation</i> , <b>2008</b> , 26, 152-8	2.1	24
89	Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1477-1484	10.3	119
88	Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. <i>Tumor Biology</i> , <b>2008</b> , 29, 28-34	2.9	72
87	Aggressiveness of cancer-care near the end-of-life in Korea. <i>Japanese Journal of Clinical Oncology</i> , <b>2008</b> , 38, 381-6	2.8	85
86	End-of-life Decision in Korea. <i>Journal of the Korean Medical Association</i> , <b>2008</b> , 51, 524	0.5	9

85	Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , <b>2008</b> , 30, 346-50	4.2	6
84	Upfront chemotherapy and involved-field radiotherapy results in more relapses than extended radiotherapy for intracranial germinomas: modification in radiotherapy volume might be needed. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 667-71	4	38
83	Palliative chemotherapy for pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , <b>2007</b> , 58, 112-5	5.9	111
82	Nonsurgical Treatment of an Incompletely Excised Primary Adenocarcinoma of Nonpigmented Ciliary Epithelium. <i>Tumori</i> , <b>2007</b> , 93, 514-517	1.7	2
81	Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. <i>Journal of Korean Medical Science</i> , <b>2007</b> , 22 Suppl, S115-21	4.7	22
80	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , <b>2007</b> , 7, 203	4.8	111
79	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , <b>2007</b> , 7, 63	4.8	55
78	Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?. <i>General Hospital Psychiatry</i> , <b>2007</b> , 29, 555-61	5.6	15
77	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , <b>2007</b> , 15, 631-636	3.9	13
76	Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5233-9	2.2	150
75	Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment. <i>Acta Oto-Laryngologica</i> , <b>2007</b> , 121-7	1.6	3
74	Chemotherapy use and associated factors among cancer patients near the end of life. <i>Oncology</i> , <b>2007</b> , 72, 164-71	3.6	55
73	Validation study of the Korean version of the McGill Quality of Life Questionnaire. <i>Palliative Medicine</i> , <b>2007</b> , 21, 441-7	5.5	24
72	M20-03: Decision-making of lung cancer patients and family. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S211-S212	5.2	12
71	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 313-9	1.9	49
70	Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1502-10	4.6	7
69	High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4232-6	12.9	34
68	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2538-44	12.9	215

67	Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. <i>Molecular Therapy</i> , <b>2006</b> , 13, 899-909	11.7	24
66	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1274-82	1.9	51
65	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2006</b> , 36, 344-50	2.8	25
64	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , <b>2006</b> , 52, 75-81	5.9	9
63	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , <b>2006</b> , 54, 201-7	5.9	31
62	Patient-reported assessment of quality care at end of life: development and validation of Quality Care Questionnaire-End of Life (QCQ-EOL). <i>European Journal of Cancer</i> , <b>2006</b> , 42, 2310-7	7.5	30
61	Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. <i>Journal of Korean Medical Science</i> , <b>2006</b> , 21, 633-8	4.7	5
60	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. <i>Supportive Care in Cancer</i> , <b>2006</b> , 14, 103-8	3.9	55
59	EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units. <i>Supportive Care in Cancer</i> , <b>2006</b> , 14, 329-33	3.9	34
58	Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. <i>Oncogene</i> , <b>2005</b> , 24, 6689-98	9.2	45
57	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2493-501	2.2	681
56	Overexpression of Surface-Bound TGF- $\beta$ 1 in Head & Neck Cancer Cell Lines Via Activated Immune Effector Cells-Derived Factors. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 619	5	
55	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , <b>2005</b> , 106, 3785-90	2.2	145
54	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 109-15	7.5	139
53	Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 565-72	3.9	57
52	Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. <i>Journal of Korean Medical Science</i> , <b>2005</b> , 20, 806-10	4.7	16
51	Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2005</b> , 35, 380-5	2.8	14
50	Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2005</b> , 35, 720-6	2.8	17



49	Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2005</b> , 35, 6-12	2.8	4
48	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. <i>The Korean Journal of Hematology</i> , <b>2005</b> , 40, 192		
47	Neoadjuvant Chemotherapy Followed by Radiotherapy in Epidermoid Carcinoma of Anus. <i>Tumori</i> , <b>2004</b> , 90, 299-302	1.7	1
46	Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 3708-16	12.9	644
45	Tracheal glomangiosarcoma with multiple skin metastasis. <i>Journal of Dermatology</i> , <b>2004</b> , 31, 776-8	1.6	9
44	The attitudes of cancer patients and their families toward the disclosure of terminal illness. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 307-14	2.2	147
43	Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. <i>Cancer Research</i> , <b>2004</b> , 64, 3230-5	10.1	32
42	Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , <b>2004</b> , 34, 400-4	2.8	19
41	Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. <i>Journal of Immunology</i> , <b>2004</b> , 172, 7335-40	5.3	417
40	Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. <i>Oncology</i> , <b>2004</b> , 66, 439-44	3.6	109
39	Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. <i>Cancer Gene Therapy</i> , <b>2004</b> , 11, 570-6	5.4	11
38	Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , <b>2004</b> , 26, 706-15	4.2	7
37	Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. <i>Cancer</i> , <b>2004</b> , 100, 1961-6	6.4	67
36	Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. <i>Cancer</i> , <b>2004</b> , 101, 2257-60	6.4	61
35	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , <b>2004</b> , 101, 2516-22	6.4	13
34	Clinicopathologic features of surgically resected primary gastric lymphoma. <i>World Journal of Gastroenterology</i> , <b>2004</b> , 10, 1103-9	5.6	2
33	Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. <i>Acta Oncologica</i> , <b>2003</b> , 42, 779-83	3.2	66
32	Comparative analysis of NK/T-cell lymphoma and peripheral T-cell lymphoma in Korea: Clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1. <i>Pathology International</i> , <b>2003</b> , 53, 735-43	1.8	29

31	Multicenter study of pain and its management in patients with advanced cancer in Korea. <i>Journal of Pain and Symptom Management</i> , <b>2003</b> , 25, 430-7	4.8	49
30	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. <i>Cancer</i> , <b>2003</b> , 98, 2651-6	6.4	52
29	Inhibitory effect of p27KIP1 gene transfer on head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , <b>2003</b> , 25, 44-9	4.2	16
28	The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 729-38	7.5	60
27	Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 39, 99-101	5.9	25
26	Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , <b>2003</b> , 33, 608-12	2.8	64
25	Chylothorax in Gorham's disease. <i>Journal of Korean Medical Science</i> , <b>2002</b> , 17, 826-9	4.7	23
24	Survival of all cancer patients in Korea through 2-year follow-up. <i>Journal of Korean Medical Science</i> , <b>2002</b> , 17, 448-52	4.7	0
23	Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 54, 414-9	4	95
22	Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. <i>Japanese Journal of Cancer Research</i> , <b>2002</b> , 93, 471-7		90
21	Progress and limitations in cancer gene therapy. <i>Genetics in Medicine</i> , <b>2002</b> , 4, 52S-55S	8.1	12
20	Docetaxel 75 mg/m <sup>2</sup> is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. <i>Japanese Journal of Clinical Oncology</i> , <b>2002</b> , 32, 248-54	2.8	92
19	A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2002</b> , 25, 238-43	2.7	39
18	Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. <i>Clinical and Experimental Dermatology</i> , <b>2001</b> , 26, 242-7	1.8	41
17	A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. <i>Cancer</i> , <b>2001</b> , 91, 1549-56	6.4	12
16	Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. <i>Head and Neck</i> , <b>2001</b> , 23, 713-7	4.2	35
15	Prognostic factors of Krukenberg's tumor. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 105-9	4.9	68
14	Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. <i>European Journal of Surgical Oncology</i> , <b>2001</b> , 27, 464-71	3.6	34

13	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. <i>Cancer</i> , <b>2000</b> , 89, 2521-6	6.4	30
12	Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 216-22	4.5	16
11	A Spindle Cell Tumor of Unknown Origin and Diffuse Bone Marrow Involvement in a Patient with Hypercalcemia. <i>Tumori</i> , <b>1999</b> , 85, 526-529	1.7	1
10	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 45, 901-5	4	18
9	Risk factors for ovarian metastasis following curative resection of gastric adenocarcinoma <b>1999</b> , 85, 1490-1499	25	
8	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. <i>Cancer</i> , <b>1999</b> , 86, 1109-15	6.4	21
7	Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , <b>1999</b> , 60, 205-14	7.1	46
6	Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II). <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 41, 109-16	3.5	6
5	Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors. <i>International Journal of Cancer</i> , <b>1998</b> , 77, 907-12	7.5	12
4	Neoadjuvant chemotherapy and radiotherapy for the treatment of advanced hypopharyngeal carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>1998</b> , 19, 40-4	2.8	10
3	Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. <i>Human Gene Therapy</i> , <b>1998</b> , 9, 2031-8	4.8	11
2	A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , <b>1993</b> , 71, 3813-8	6.4	323
1	Enhancement of adenoviral transduction with polycationic liposomes in vivo		14